American Portfolios Advisors Oncocyte Corp Transaction History

American Portfolios Advisors

  • $2.36 Trillion
  • Q3 2022

A detailed history of American Portfolios Advisors transactions in Oncocyte Corp stock. As of the latest transaction made, American Portfolios Advisors holds 21,830 shares of OCX stock, worth $58,504. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,830
Holding current value
$58,504
% of portfolio
0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023
BUY
$0.76 - $15.98 $16,590 - $348,843
21,830 New
21,830 $15.9 Million
Q1 2022

Mar 21, 2023
SELL
$1.15 - $2.25 $11,500 - $22,500
-10,000 Reduced 45.81%
11,830 $17.6 Million
Q4 2021

Mar 21, 2023
SELL
$2.04 - $3.59 $19,176 - $33,746
-9,400 Reduced 43.06%
12,430 $27 Million
Q3 2021

Mar 22, 2023
SELL
$3.53 - $5.89 $33,005 - $55,071
-9,350 Reduced 42.83%
12,480 $44.4 Million
Q2 2021

Mar 22, 2023
SELL
$3.77 - $6.0 $35,249 - $56,100
-9,350 Reduced 42.83%
12,480 $71.6 Million
Q1 2021

Mar 22, 2023
SELL
$2.39 - $6.5 $22,346 - $60,775
-9,350 Reduced 42.83%
12,480 $64.8 Million
Q4 2020

Mar 22, 2023
SELL
$1.38 - $2.63 $29,297 - $55,834
-21,230 Reduced 97.25%
600 $1.43 Million
Q3 2020

Mar 22, 2023
SELL
$1.2 - $1.89 $25,410 - $40,020
-21,175 Reduced 97.0%
655 $910,000
Q1 2020

Mar 24, 2023
SELL
$1.76 - $3.02 $33,396 - $57,304
-18,975 Reduced 86.92%
2,855 $7 Million
Q4 2019

Mar 24, 2023
SELL
$1.51 - $2.27 $30,917 - $46,478
-20,475 Reduced 93.79%
1,355 $3.05 Million
Q3 2019

Mar 24, 2023
SELL
$1.59 - $2.51 $32,555 - $51,392
-20,475 Reduced 93.79%
1,355 $2.85 Million

Others Institutions Holding OCX

# of Institutions
3
Shares Held
411K
Call Options Held
0
Put Options Held
0
View Full List

About Oncocyte Corp

OCX Quotes by TradingView
  • Ticker OCX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,609,000
  • Market Cap $318M
  • Description
  • OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....
More about OCX
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email